2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

www.kumc.edu

 

Head & Neck
08:12

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Understanding the Distinction of HPV-Mediated (p16+) Oropharynx Cancer from Overall Head&Neck Cancers

FEATURING Gregory Gan
  • 92 views
  • November 12, 2019
12:23

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

De-Escalation of HPV-Mediated (p16+) Oropharynx Cancer Treatment: Rationale for Altered and Radiotherapy, and Surgery Followed by Radiation De-Escalation

FEATURING Gregory Gan
  • 23 views
  • November 12, 2019
10:27

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

De-Escalation of HPV-Mediated (p16+) Oropharynx Cancer Treatment: TORS vs. Definitive (Chemo)Radiotherapy / Future Directions - Proton Therapy

FEATURING Gregory Gan
  • 207 views
  • November 12, 2019
19:34

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Evaluation and Managing Options of the Adult Neck Mass in the Era of Human Papilloma Virus

FEATURING Andres M. Bur
  • 275 views
  • November 12, 2019
  • 2
06:51

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on the HPV+ Oropharynx Carcinoma: Cisplatin and Concurrent Radiation Therapy Remain Standard of Care for Non-Smokers Eligible for Cisplatin Chemotherapy

FEATURING Prakash Neupane
  • 41 views
  • November 12, 2019
06:20

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Locally Advanced Nasopharyngeal Cancer: Induction Chemo + Concurrent Chemoradiation Therapy Established Is Current Standard of Care

FEATURING Prakash Neupane
  • 46 views
  • November 12, 2019
08:21

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Recurrent/Metastatic Head&Neck Squamous Cell Carcinoma: 1st Line Pembro for PDL1 CPS>1%, or Carbo+5FU+Pembro for All Is the New Standard of Care

FEATURING Prakash Neupane
  • 569 views
  • November 12, 2019
12:55

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Salivary Gland Carcinoma: Anti-HER2 w/o or w/Chemo Docetaxel Is Highly Active for Salivary Duct, Levatinib As Palliative for Recurrent/Metastatic Adenoid Cystic Carcinoma

FEATURING Prakash Neupane
  • 39 views
  • November 12, 2019